Related Experiment Videos

Effects of anorectic agents in rats bearing the Walker-256 tumor

R P Maickel1, K Johnson, D R Kinney

  • 1Department of Pharmacology and Toxicology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907.

Research Communications in Chemical Pathology and Pharmacology
|December 1, 1987
PubMed

Insights

This study investigated anorectic agents in tumor-bearing rats, finding no conclusive evidence that d-amphetamine, fenfluramine, or mazindol primarily affect dopaminergic, noradrenergic, or serotonergic systems to cause anorexia.

Area of Science:

  • Neuropharmacology
  • Oncology
  • Behavioral Neuroscience

Background:

  • Biogenic amine level alterations observed in brain regions of rats with Walker-256 tumors.
  • Anorexia is a common symptom associated with cancer, impacting patient outcomes.

Purpose of the Study:

  • To evaluate the effects of three anorectic agents on tumor-bearing rats.
  • To determine if these agents' anorectic effects are linked to specific neurotransmitter systems.

Main Methods:

  • Administration of d-amphetamine, fenfluramine, and mazindol to rats with Walker-256 tumors.
  • Assessment of drug effects on days 5 and 8 post-tumor implantation.

Main Results:

  • No conclusive evidence of predominant dopaminergic, noradrenergic, or serotonergic system involvement in the anorectic effects.
  • The tested anorectic agents did not show a clear link to specific neurotransmitter pathways in this model.

Conclusions:

  • The anorectic effects of d-amphetamine, fenfluramine, and mazindol in Walker-256 tumor-bearing rats are not conclusively attributable to major modifications in dopaminergic, noradrenergic, or serotonergic systems.
  • Further research is needed to elucidate the mechanisms underlying anorexia in this cancer model.

Related Concept Videos